ImmunityBio (IBRX) Interest Expenses (2016 - 2026)

ImmunityBio (IBRX) has reported Interest Expenses for 13 consecutive years, with $77.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest Expenses rose 394.28% year-over-year to $77.1 million; the TTM figure through Mar 2026 stood at $77.1 million (down 23.48% YoY), while the FY2025 annual figure was $855.8 million, up 10.13% from the prior year.
• Interest Expenses improved to $77.1 million in Q1 2026 per IBRX's latest filing, from $14.8 million in the prior quarter.
• Across five years, Interest Expenses topped out at $77.1 million in Q1 2026 and bottomed at -$18.7 million in Q4 2022.
• Historically, Interest Expenses has averaged $21.6 million across 5 years, with a median of $16.8 million in 2022.
• Annual changes were most pronounced in 2022 — Interest Expenses plunged 515.43% — and 2024, when it soared 6405.25%.
• ImmunityBio's Interest Expenses stood at -$18.7 million in 2022, then soared by 102.14% to $400000.0 in 2023, then jumped by 6405.25% to $26.0 million in 2024, then slumped by 42.96% to $14.8 million in 2025, then soared by 419.25% to $77.1 million in 2026.
• Business Quant data shows IBRX's Interest Expenses at $77.1 million in Q1 2026, $14.8 million in Q4 2025, and $15.3 million in Q3 2025.